Matches in SemOpenAlex for { <https://semopenalex.org/work/W2331511244> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2331511244 endingPage "491" @default.
- W2331511244 startingPage "487" @default.
- W2331511244 abstract "Purpose: A Phase II study to evaluate the effect of a five-drug regimen, VP-16, ifosfamide, cisplatin, vinblastine, and bleomycin (VIP/VB) on complete response rate, continuous disease-free survival, and toxicity in patients with advanced germ-cell tumor. Patients and methods: Twenty male patients with a histologic diagnosis of advanced-stage germ-cell cancer, previously untreated with chemotherapy, received the following: etoposide 75 mg/m2 i.v. days 1-5; ifosfamide (with mesna uroprotection) 1.2 g/m2 i.v. days 1-5; cisplatin 20 mg/m2 i.v. days 1-5; vinblastine 0.18 mg/kg i.v. day 1; bleomycin 30 units i.v. day 1; filgrastim 5 μg/kg days 7-16. Chemotherapy was given every 3 weeks (bleomycin weekly × 12) for four courses. Results: All patients entered were evaluable for toxicity, response, and survival. Eleven of 20 (55%) achieved complete remissions with chemotherapy alone and an additional 5 (25%) were rendered disease-free with surgical resection of teratoma (3) or viable cancer (2). Two patients relapsed at 4 and 5 months from complete remission (CR). There was one treatment-related death, from bleomycin lung toxicity after thoracotomy. Thirteen patients (65%) are alive and continuously free of disease, with a median follow-up of 20 months and a minimal follow-up of 12 months. Hematologic toxicity was most common, with 16 patients (80%) having grade 3 or 4 leukopenia. Conclusion: VIP/VB appears to be a very active regimen in advanced disseminated germcell cancer. Hematological toxicity was severe but manageable." @default.
- W2331511244 created "2016-06-24" @default.
- W2331511244 creator A5021904320 @default.
- W2331511244 creator A5048544130 @default.
- W2331511244 creator A5048660181 @default.
- W2331511244 creator A5070973399 @default.
- W2331511244 date "1996-10-01" @default.
- W2331511244 modified "2023-10-14" @default.
- W2331511244 title "A Phase II Trial of VP-16, Ifosfamide, Cisplatin, Vinblastine, and Bleomycin in Advanced Germ-Cell Tumors" @default.
- W2331511244 cites W1861752925 @default.
- W2331511244 cites W1956443396 @default.
- W2331511244 cites W1970781080 @default.
- W2331511244 cites W1983482625 @default.
- W2331511244 cites W2028988288 @default.
- W2331511244 cites W2094521253 @default.
- W2331511244 cites W2267740990 @default.
- W2331511244 cites W2323139555 @default.
- W2331511244 doi "https://doi.org/10.1097/00000421-199610000-00012" @default.
- W2331511244 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8823477" @default.
- W2331511244 hasPublicationYear "1996" @default.
- W2331511244 type Work @default.
- W2331511244 sameAs 2331511244 @default.
- W2331511244 citedByCount "9" @default.
- W2331511244 countsByYear W23315112442016 @default.
- W2331511244 countsByYear W23315112442018 @default.
- W2331511244 crossrefType "journal-article" @default.
- W2331511244 hasAuthorship W2331511244A5021904320 @default.
- W2331511244 hasAuthorship W2331511244A5048544130 @default.
- W2331511244 hasAuthorship W2331511244A5048660181 @default.
- W2331511244 hasAuthorship W2331511244A5070973399 @default.
- W2331511244 hasConcept C126322002 @default.
- W2331511244 hasConcept C141071460 @default.
- W2331511244 hasConcept C2776232574 @default.
- W2331511244 hasConcept C2776694085 @default.
- W2331511244 hasConcept C2776938808 @default.
- W2331511244 hasConcept C2777132456 @default.
- W2331511244 hasConcept C2777506904 @default.
- W2331511244 hasConcept C2778119113 @default.
- W2331511244 hasConcept C2780376820 @default.
- W2331511244 hasConcept C2780873365 @default.
- W2331511244 hasConcept C2781413609 @default.
- W2331511244 hasConcept C29730261 @default.
- W2331511244 hasConcept C71924100 @default.
- W2331511244 hasConcept C90924648 @default.
- W2331511244 hasConceptScore W2331511244C126322002 @default.
- W2331511244 hasConceptScore W2331511244C141071460 @default.
- W2331511244 hasConceptScore W2331511244C2776232574 @default.
- W2331511244 hasConceptScore W2331511244C2776694085 @default.
- W2331511244 hasConceptScore W2331511244C2776938808 @default.
- W2331511244 hasConceptScore W2331511244C2777132456 @default.
- W2331511244 hasConceptScore W2331511244C2777506904 @default.
- W2331511244 hasConceptScore W2331511244C2778119113 @default.
- W2331511244 hasConceptScore W2331511244C2780376820 @default.
- W2331511244 hasConceptScore W2331511244C2780873365 @default.
- W2331511244 hasConceptScore W2331511244C2781413609 @default.
- W2331511244 hasConceptScore W2331511244C29730261 @default.
- W2331511244 hasConceptScore W2331511244C71924100 @default.
- W2331511244 hasConceptScore W2331511244C90924648 @default.
- W2331511244 hasIssue "5" @default.
- W2331511244 hasLocation W23315112441 @default.
- W2331511244 hasLocation W23315112442 @default.
- W2331511244 hasOpenAccess W2331511244 @default.
- W2331511244 hasPrimaryLocation W23315112441 @default.
- W2331511244 hasRelatedWork W1495274529 @default.
- W2331511244 hasRelatedWork W1975212853 @default.
- W2331511244 hasRelatedWork W2119963083 @default.
- W2331511244 hasRelatedWork W2236809524 @default.
- W2331511244 hasRelatedWork W2243919485 @default.
- W2331511244 hasRelatedWork W2323139555 @default.
- W2331511244 hasRelatedWork W2331511244 @default.
- W2331511244 hasRelatedWork W2410086843 @default.
- W2331511244 hasRelatedWork W2418332155 @default.
- W2331511244 hasRelatedWork W2419130448 @default.
- W2331511244 hasVolume "19" @default.
- W2331511244 isParatext "false" @default.
- W2331511244 isRetracted "false" @default.
- W2331511244 magId "2331511244" @default.
- W2331511244 workType "article" @default.